The impact of the hepatitis B virus vaccine on the incidence of hepatitis B virus-associated membranous nephropathy

Archives of Pediatrics and Adolescent Medicine

Volumn 157, Issue 10, 2003, Pages 1025-1030

  Bhimma, Rajendra ^a   Coovadia, Hoosen Mahomed ^a   Adhikari, Miriam ^a   Connolly, Catherine Anne ^b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADOLESCENT; ARTICLE; CHILD; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH PROGRAM; HEPATITIS B; HUMAN; IMMUNIZATION; INCIDENCE; INFECTION PREVENTION; KIDNEY BIOPSY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SOUTH AFRICA; SOUTHEAST ASIA; STATISTICAL SIGNIFICANCE; VACCINATION;

ADOLESCENT; AGE FACTORS; CHILD; CHILD WELFARE; CHILD, PRESCHOOL; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION; INCIDENCE; INFANT; INFANT WELFARE; INFANT, NEWBORN; MALE; PATIENT ADMISSION; SOUTH AFRICA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0141864526     PISSN: 10724710     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpedi.157.10.1025     Document Type: Article

References (43)

1. Whittle HC, Pilkington J, Mendy M, et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet. 1995;345:1089-1092.
2. Kew MC. Protective efficacy of hepatitis B vaccination. Lancet. 1995;345:1065-1066.
3. Hsu HM, Chen DS, Chaung CH, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. JAMA. 1988;260:2231-2235.
4. Tsen YJ, Chang MH, Hsu HY, Lee CY, Sung JL, Chen DS. Seroprevalence of hepatitis B virus infection in children in Taipei, 1989: five years after a mass hepatitis B vaccination program. J Med Virol. 1991;34:96-99.
5. Wu WS, Shao ZP. A review of hepatitis B immunisation. Chin J Vaccine Immun. 1996;2:61-66.
6. Line XM, Xu ZY, Ouyang PY, et al. Eight year survey for hepatitis B vaccine efficacy to newborns after universal immunisation. Chin J Exp Virol. 1995;9(suppl): 55-58.
7. Li RC, Yang JY, Wang SS, et al. The effect of hepatitis B vaccination on epidemiology of hepatitis virus. Chin J Vaccine Immun. 1996;2:56-60.
8. Safary A, Beck J. Vaccination against hepatitis B: current challenges for Asian countries and future directions. J Gastroenterol Hepatol. 2000;15:396-401.
9. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22707 men in Taiwan. Lancet. 1981;2:1129-1133.
10. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med. 1997;336:1855-1859.
11. Zhao S, Xu Z, Lu Y. A mathematical model of hepatitis B virus transmission and its application for vaccination strategy in China. Int J Epidemiol. 2000;29:744-752.
12. Zuckerman AJ. Prevention of primary liver cancer by immunization. N Engl J Med. 1997;336:1906-1907.
13. Lee CL, Ko YC. Hepatitis B vaccination and hepatocellular carcinoma in Taiwan. Pediatrics. 1997;99:351-353.
14. Chen DS, Sung JL. Hepatitis B virus infection and chronic liver disease in Taiwan. Acta Hepatogastroenterol (Stuttg). 1978;25:423-430.
15. Kane M. Status of hepatitis V immunisation programmes in 1998. Vaccine. 1998;16(suppl):S104-S108.
16. Kiire CF. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. Gut. 1996;38(suppl 2):S5-S12.
17. Kew MC. Progress towards the comprehensive control of hepatitis B in Africa: a view from South Africa. Gut. 1996;38(suppl 2):S31-S36.
18. Robson WS, Kirsch RE. National strategy for viral hepatitis: recommendations and guidelines for management in South Africa. S Afr Med J. 1991;80:347-356.
19. Whittle HC, Bradley HK, McLauchan K, et al. Hepatitis B virus infection in two Gambian villages. Lancet. 1983;1:1203-1206.
20. Prozesky OW, Szmuness W, Stevens CE, et al. Baseline epidemiological studies for a hepatitis B vaccine trial in Kangwane. S Afr Med J. 1983;64:891-893.
21. Botha JF, Ritchie MJJ, Dusheiko GM, Mouton HWK, Kew MC, Hepatitis B virus carrier state in black children in Ovamboland: role of perinatal and horizontal infection. Lancet. 1984;1:1210-1212.
22. Barin F, Perrin J, Chotard J, et al. Cross-sectional and longitudinal epidemiology of hepatitis B in Senegal. Prog Med Virol. 1981;27:148-162.
23. Vos GH, Rose EF, Marimuthu T. Hepatitis B antigen and antibodies in rural and urban southern African blacks. S Afr Med J. 1980;57:868-870.
24. Rodney DG, Wiggelinkhuizen J. The clinical course of hepatitis B virus-associated nephropathy. Pediatr Nephrol. 1994;8:11-14.
25. Bhimma R, Coovadia HM, Adhikari M. Hepatitis B virus-associated nephropathy in black South African children. Pediatr Nephrol. 1998;12:479-484
26. Coovadia HM, Adhikari M, Moodley D. Hepatitis B "s" and "e" antigen carriage in childhood nephrotic syndrome predicts membranous glomerulonephritis. Ann Trop Paediatr. 1993;13:79-82.
27. Levy M, Chen N. Worldwide perspective of hepatitis B-associated glomerulonephritis in the 80s. Kidney Int Suppl. 1991;35:S24-S33.
28. Bhimma R, Coovadia HM, Adhikari M. Nephrotic syndrome in South African children: changing perspectives over 20 years. Pediatr Nephrol. 1997;11:429-437.
29. Seggie J, Nathoo K, Davies PG. Association of hepatitis B (HBs) antigenaemia and membranous glomerulonephritis in Zimbabwean children. Nephron. 1984;38:115-119.
30. Hsu HC, Lin GH, Chang MH, Chen CH. Association of hepatitis B surface (HBs) antigenemia and membranous nephropathy in children in Taiwan. Clin Nephrol. 1983;20:121-129.
31. Aspinall S. Effectiveness of low-cost hepatitis B vaccine in the South African EPI programme: field trial results. Epidemiol Comments. 1995;22:8-10.
32. The people of South Africa: population census 1996. Stat S Afr. 1998;September: 14-22.
33. Coovadia HM, Adhikari M, Morel-Maroger L. Clinico-pathological features of the nephrotic syndrome in South African children. Q J Med. 1979;48:77-91.
34. Wrzolkowa T, Zurowska A, Mrozowicz-Picken M. Hepatitis B virus associated glomerulonephritis: electron microscopic studies in 98 children. Am J Kidney Dis. 1991;18:306-312.
35. Yoshikawa N, Ito H, Yamada Y, et al. Membranous glomerulonephritis associated with hepatitis B antigen in children: a comparison with idiopathic membranous glomerulonephritis. Clin Nephrol. 1985;23:28-34.
36. Aspinall S, Kocks KJ. Immunogenicity of a low-cost hepatitis B vaccine in the South African Expanded Programme on Immunisation. S Afr Med J 1998;88:36-39.
37. Department of Health. South Africa Demographic and Health Survey: Preliminary Report. Durban, South Africa: Health Systems Trust; 2001:10.
38. Bhimma R, Coovadia HM, Kramvis A, Adhikari M, Kew MC, Connolly CA. HBV and proteinuria in relatives and contacts of children with hepatitis B virus-associated membranous nephropathy. Kidney Int. 1999;55:2440-2449.
39. Tsebe KV, Burnett RJ, Hlungwani NP, Sibara MM, Venter PA, Mphalhlele MJ. The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year olds. Vaccine. 2001;19:3919-3926.
40. Adhikari M, Coovadia HM, Chrystal V. Extramembranous nephropathy in black South African children. Ann Trop Paediatr. 1983;3:17-24.
41. Vardas E, Mathai M, Blaau D, McAnerney J, Coppin A, Sim J. Preimmunisation epidemiology of hepatitis B virus infection in South African children. J Med Virol 1999;58:111-115.
42. Karim SSA, Thelpal R, Coovadia HM, Household clustering and intra-household transmission patterns of hepatitis B virus infection in South Africa. Int J Epidemiol. 1991;20:495-503.
43. Department of Health. Health systems research: research co-ordination and epidemiology. Available at: http://www.196.36.153.56/doh/facts/notify/2001. Accessed March 14, 2002.